roblan-shutterstock-com
Roblan / Shutterstock.com
25 November 2015Americas

Kyle Bass targets Alpex speckled tablet patent

Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board (PTAB) review the validity of a patent owned by Alpex Pharma.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
2 December 2015   Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.

More on this story

Big Pharma
2 December 2015   Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.

More on this story

Big Pharma
2 December 2015   Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.